215 related articles for article (PubMed ID: 16537192)
21. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
22. Pyrimidine degradation defects and severe 5-fluorouracil toxicity.
van Kuilenburg AB; Meinsma R; van Gennip AH
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1371-5. PubMed ID: 15571261
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB; De Abreu RA; van Gennip AH
Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
[TBL] [Abstract][Full Text] [Related]
25. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.
Magné N; Etienne-Grimaldi MC; Cals L; Renée N; Formento JL; Francoual M; Milano G
Br J Clin Pharmacol; 2007 Aug; 64(2):237-40. PubMed ID: 17335544
[TBL] [Abstract][Full Text] [Related]
26. [Detection of dihydropyrimidine dehydrogenase deficiency before treatment by fluoropyrimidines].
Gamelin E; Boisdron-Celle M; Morel A
Therapie; 2007; 62(2):99-103. PubMed ID: 17582309
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
28. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
29. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
[TBL] [Abstract][Full Text] [Related]
30. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
31. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Saif MW; Seller S; Diasio RB
JOP; 2008 Mar; 9(2):226-9. PubMed ID: 18326935
[TBL] [Abstract][Full Text] [Related]
32. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
33. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
Gross E; Seck K; Kiechle M
Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene.
van Kuilenburg AB; Maring JG; Schalhorn A; Terborg C; Schmalenberg H; Behnke D; Schwabe W; Jabschinsky K; Hausler P
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):692-8. PubMed ID: 18600527
[TBL] [Abstract][Full Text] [Related]
35. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
[TBL] [Abstract][Full Text] [Related]
36. [Dihydropirymidine dehydrogenase (DPD)--a toxicity marker for 5-fluorouracil?].
Jedrzychowska A; Dołegowska B
Ann Acad Med Stetin; 2013; 59(2):48-53. PubMed ID: 25026750
[TBL] [Abstract][Full Text] [Related]
37. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
38. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
[TBL] [Abstract][Full Text] [Related]
39. Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy.
Schneider HB; Becker H
Anticancer Res; 2004; 24(2C):1091-2. PubMed ID: 15154628
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
